ChemBriefNuclide Therapeutics builds leaner radiopharmaceuticals
Nuclide Therapeutics raised £5 million to initiate its first clinical trial for anticancer radiopharmaceuticals utilizing theranostic molecules. The London-based firm targets dosing its first patient
cen · 2026-10-12 00:00